Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced that its representatives will participate in the IPAC-RS 2026 Nasal Innovation Forum, scheduled for Sept. 16-17, 2026, in Jersey City, New Jersey. The forum provides a platform for experts in nasal drug development to discuss innovations and challenges in the field, an opportunity that aligns with Silo's strategic focus on advancing its lead candidate, SPC-15.
CEO Eric Weisblum emphasized the importance of the forum in fostering collaboration and knowledge exchange. "This forum offers a valuable opportunity to engage with experts in nasal drug development as we continue to advance SPC-15's novel nose-to-brain approach for targeted drug delivery in the treatment of PTSD," Weisblum stated. The company's participation underscores its commitment to addressing underserved conditions through innovative delivery mechanisms.
SPC-15 is designed to deliver therapeutics directly to the brain via the nasal route, potentially offering faster onset and improved efficacy compared to traditional systemic administration. Preclinical data presented by the company demonstrate that the SPC-15 formulation and device met predefined specifications for assay, impurities, pH, and microbiological quality over a nine-month period. Additionally, six-month accelerated stability data were consistent with long-term stability findings, supporting the product's potential for further development.
The IPAC-RS forum is a key event for the inhalation and nasal drug development community, bringing together researchers, regulators, and industry leaders to discuss scientific and regulatory topics. Silo's participation highlights its active role in advancing nasal drug delivery technologies. The company's pipeline includes other programs targeting chronic pain and CNS diseases, such as SP-26 for fibromyalgia and chronic pain, and preclinical assets for Alzheimer's disease and multiple sclerosis.
This announcement comes as Silo Pharma continues to expand its research collaborations with leading universities and laboratories. The company's focus on nose-to-brain delivery could offer new hope for patients with PTSD, a condition that affects millions worldwide and has limited effective treatment options. By participating in this forum, Silo aims to stay at the forefront of innovation in this therapeutic area.
For more information about Silo Pharma and its programs, visit the company's website at silopharma.com. The full press release is available at this link.
